Venture capital firm Frazier Healthcare Partners has added Chris Peetz to the Life Sciences team as an Entrepreneur-in-Residence (EIR).
Most recently, Mr. Peetz served as Chief Financial Officer and Head of Corporate Development at Frazier portfolio company Tobira Therapeutics, a developer of therapeutics to treat non-alcoholic steatohepatitis (NASH). While at Tobira, Mr. Peetz led the company’s efforts to become a public company through a reverse merger, expand its pipeline through partnerships and in-licensing, and sell the company to Allergan for total consideration of up to $1.7 billion.
Prior to Tobira, he held business leadership roles at Jennerex Biotherapeutics, Onyx Pharmaceuticals and Abgenix.
As an EIR with Frazier, Mr. Peetz will focus on identifying and in-licensing assets into a newly formed search company, Flashlight Therapeutics. Mr. Peetz serves as the CEO of Flashlight, which is broadly focused on oncology, liver diseases and NASH, and related areas.
Led by Patrick Heron, Managing General Partner with the Life Sciences team, Frazier provides growth and venture capital to healthcare companies. With nearly $3.0 billion total capital raised, the firm has invested in over 170 companies, with investment types ranging from company creation and venture capital to buyouts of profitable lower-middle market companies.
The Growth Buyout team invests in healthcare and pharmaceutical services, medical products and related sectors.
The Life Sciences team invests in therapeutics and related areas that are addressing unmet medical needs through innovation.
Frazier has offices in Seattle, WA and Menlo Park, CA, and invests broadly across the US, Canada, and Europe.